This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
DT2216, a proteolysis-targeting chimera (PROTAC), effectively targets BCL-XLfor degradation.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
February 2020
Volume 10, Issue 2
Volume 10, Issue 2
The PROTAC DT2216 Targets Cancer by Promoting BCL-XL Degradation
Jump to section
Advertisement